Sentences with phrase «by pembrolizumab»

In the first phase of MasterKey, T - VEC was injected into the tumors of 21 patients with advanced melanoma, followed by pembrolizumab immunotherapy.

Not exact matches

Pembrolizumab, which is marketed under the brand name Keytruda, works by turning off the immune system's brakes, allowing its T cells to recognize and attack cancer cells.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

Of those treated with pembrolizumab and platinum + pemetrexed, the risk of death was reduced by 51 %, compared to those treated with platinum + pemetrexed alone.

In Cohort A, pembrolizumab shrunk tumors by more than 30 percent in eight of 170 patients, or five percent, and stabilized the disease in 35, or 21 percent, of those previously treated for mTNBC.

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Center.

By injecting T - VEC into the patients» tumors, even those that were located deeper in the body, the researchers were able to transform cold tumors into hot ones, which in turn allowed pembrolizumab to deliver a beneficial enhancement.

The investigators found that pembrolizumab significantly improved the primary endpoint of progression - free survival by approximately four months compared to chemotherapy (10.3 months versus 6.0 months, hazard ratio [HR] 0.50).

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.

«By causing fewer side effects and promoting longer life expectancy, pembrolizumab could help change the outcome of mTNBC.»

Pembrolizumab, marketed under the name Keytruda, was well tolerated by both cohorts at a 200 mg dose every three weeks, according to study results.

The KEYNOTE - 45 study randomised 542 patients from 29 countries between November 2014 and November 2015 to either pembrolizumab (200 mg, given intravenously once every three weeks for up to 24 months) or one of three chemotherapy options chosen by study investigators.

Pembrolizumab works by binding to PD - 1 and blocking the interaction between PD - 1 and its ligands, PD - L1 and PD - L2, thereby activating T lymphocyte cells which may affect both tumour cells and healthy cells.

PD -1-blocking agents such as nivolumab, pembrolizumab and atezolizumab are part of a class of drugs known as checkpoint inhibitors, and many cancer researchers are now trying to figure out how to enhance their activity by combining them with other types of drugs.

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.

The study is funded by the biopharmaceutical company Merck & Co., which makes pembrolizumab, or Keytruda.

On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.

If approved by the FDA in October for the treatment of refractory melanoma, pembrolizumab would be the first PD - 1 checkpoint inhibitor approved in its class, beating out BMS's nivolumab in the race to the finish line — or starting line, really, since both drugs will likely have multiple future uses.

By binding to and blocking certain molecules on T cells, in this case a molecule called PD - 1, pembrolizumab «takes the brakes off» the immune response, allowing a more powerful response to cancer.

According to an international clinical trial led by Sylvia Adams, MD, associate professor of medicine, breast tumors shrank by more than 30 percent in 12 (23 percent) of 52 patients who received pembrolizumab as first - line therapy, and the disease stabilized in 9 additional patients (17 percent).

Similarly, pembrolizumab shrank tumors by at least a third in 24 percent of patients.

Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail patients with advanced bladder cancer in early 2017.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

The phase II part of a phase Ib / II study (ClinicalTrials.gov identifier: NCT02263508; MASTERKEY - 265)[24] assessing the safety and efficacy of T - VEC in combination with the PD - 1 — blocking antibody pembrolizumab in previously untreated, unresected stage IIIB / IV melanoma is evaluating confirmed ORR by irRECIST at week 24.

Pembrolizumab was approved by the FDA in 2014 and is quickly becoming the standard of care for patients with metastatic melanoma.

The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.